We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Protective Protein Drastically Reduced Following Brain Injury

By LabMedica International staff writers
Posted on 25 May 2011
The protein produced by the KCC2 gene acts to prevent damage to neurons following trauma to the brain caused by head injury, stroke, or neurodegenerative diseases such as Alzheimer's.

KCC2 is a member of the cation-chloride cotransporter gene family. More...
KCCs normally lower intracellular chloride concentrations below the electrochemical equilibrium potential and depending on the chemical concentration gradients of potassium and chloride, KCC2 can operate as a net efflux or influx pathway. KCC2 is expressed at high levels in neurons throughout the nervous system and immunofluorescence has shown that the protein was localized at inhibitory synapses of the spinal cord. Previous studies had shown that the level of KCC2 dropped drastically after brain injury.

Investigators at the Université de la Méditerranée (Marseille, France) used primary hippocampal neuronal cultures to study KCC2 function. In this system, they could block the action of KCC2 either by an RNA interference approach or by using a dominant negative mutant. KCC2 activity was restored by gene therapy that overexpressed the active form of the KCC2, while overexpression of its nonactive mutant Y1087D was used as a control.

Results published in the May 15, 2011, issue of the Journal of Physiology revealed that the experimental silencing of endogenous KCC2 reduced neuronal resistance to toxic insults. In contrast, the artificial gain of KCC2 induced by overexpression of KCC2 gene function in the same neurons protected them from death. Overexpression of the nonactive mutant Y1087D had no protective effect.

"The death of neurons in the brain can be triggered by an imbalance of oxygen – known as oxidative damage, or where cells are incorrectly instructed to die by a neurotransmitter – a process known as excitotoxicity, " said senior author Dr. Igor Medina, professor of medicine at the Université de la Méditerranée. "KCC2 protects against both. It is really encouraging that we have identified a means of potentially protecting the brain from these common conditions. The destiny of neurons in a damaged brain depends on a tiny equilibrium between prosurvival and prodeath signals. We wanted to know what KCC2 was signaling for – was it killing neurons or protecting them after an injury? Our study has found that KCC2 actually rescues the damaged cells."

"Neuroprotective agents that may stem from this research would benefit the victims of car crashes, stroke, and those suffering with epilepsy, Parkinson's, and Alzheimer's – it is a major focus for further studies," said Dr Medina.

Related Links:
Université de la Méditerranée




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.